- Home
- GGZ vs MCRB Comparison
GGZ vs MCRB Comparison
Compare GGZ & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- MCRB
- Stock Information
- Founded
- GGZ 2013
- MCRB 2010
- Country
- GGZ United States
- MCRB United States
- Employees
- GGZ N/A
- MCRB N/A
- Industry
- GGZ Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- MCRB Health Care
- Exchange
- GGZ Nasdaq
- MCRB Nasdaq
- Market Cap
- GGZ 109.0M
- MCRB 165.3M
- IPO Year
- GGZ N/A
- MCRB 2015
- Fundamental
- Price
- GGZ $14.39
- MCRB $18.94
- Analyst Decision
- GGZ
- MCRB Hold
- Analyst Count
- GGZ 0
- MCRB 4
- Target Price
- GGZ N/A
- MCRB $73.67
- AVG Volume (30 Days)
- GGZ 12.8K
- MCRB 125.0K
- Earning Date
- GGZ 01-01-0001
- MCRB 08-06-2025
- Dividend Yield
- GGZ 5.39%
- MCRB N/A
- EPS Growth
- GGZ N/A
- MCRB N/A
- EPS
- GGZ 1.75
- MCRB 10.22
- Revenue
- GGZ N/A
- MCRB N/A
- Revenue This Year
- GGZ N/A
- MCRB N/A
- Revenue Next Year
- GGZ N/A
- MCRB N/A
- P/E Ratio
- GGZ $6.79
- MCRB $1.93
- Revenue Growth
- GGZ N/A
- MCRB N/A
- 52 Week Low
- GGZ $9.43
- MCRB $6.53
- 52 Week High
- GGZ $12.50
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- GGZ 68.32
- MCRB 65.33
- Support Level
- GGZ $14.31
- MCRB $18.13
- Resistance Level
- GGZ $14.69
- MCRB $20.59
- Average True Range (ATR)
- GGZ 0.22
- MCRB 1.29
- MACD
- GGZ 0.03
- MCRB 0.08
- Stochastic Oscillator
- GGZ 69.70
- MCRB 73.52
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.